Content Type: Article

  • Key Takeaways | Hospital and Health System Digital Health Spotlight: It’s all About the Patient!

    Key Takeaways | Hospital and Health System Digital Health Spotlight: It’s all About the Patient!

    ARTICLE

    Key Takeaways | Hospital and Health System Digital Health Spotlight: It’s all About the Patient!

    August 22, 2023

    Read time: 5 min

    Key takeaways
    Overview

    During this session, leaders from health systems and digital health technology companies explored how they are leveraging their prowess to develop cutting-edge strategies to deliver accessible, easy to use and secure digital health solutions that work together seamlessly across the healthcare ecosystem and patient journey.

    Session panelists:

    • Erica Davila, general counsel, Transcarent
    • Daniel Gottlieb, partner, McDermott Will & Emery
    • Nathan Leong, vice president, legal, Memora Health
    • Sudipto Srivastava, vice president, digital transformation, Hospital for Special Surgery
    • Paul Uhrig, senior vice president, chief legal officer and digital health officer, Basset Healthcare Network
    • Moderator: Bernadette Broccolo, partner, McDermott Will & Emery
    In depth

    Top takeaways included:

    • The patient relationship is the cornerstone of any patient engagement strategy. Most, if not all, of the panelists agreed with this statement, yet they also recognize that the consumer and patient engagement solutions flooding the digital health ecosystem have cast doubt as to where the primary patient relationship should reside. For health systems, there is no doubt—they are and must remain a central, trusted partner for delivery and coordination of care across a patient’s healthcare journey. In their quest to do so, health systems are aggressively pursuing strategies that combine digital and in person touchpoints to engage individuals, both as consumers and as patients, “where they are” so they can get them to the right healthcare, at the right place and at the right time. While many digital health technology solution companies pursued “direct-to-patient” offerings early on, some quickly recognized the complexities of that model and shifted their primary focus to becoming an “extension” of health systems and payors by providing the turnkey technology infrastructure and support services they need to remain the “front door” for healthcare for patients and consumers.
    • Patients, providers and self-funded health plans want a seamless, integrated and holistic digital engagement experience. Digital engagement solutions and the data strategies supporting them have been highly fragmented and lacking integration across the patient journey and healthcare ecosystem. This is due largely to their multiple points of entry into disconnected “point-to-point solutions,” which is particularly challenging for poly-chronic patients. Providers and their patients, and self funded health plans and their members, are frustrated and clamoring for single sign on platforms through which they can engage seamlessly, in a single encounter, with digital health applications and data sources. Health systems, in particular, are looking to “fill the white space” in functionality existing between inflexible electronic health record (EHR) systems that rely exclusively on traditional patient identifiers and less formal point to point digital health solutions. Individual providers want solutions that will alleviate the burden and stress of today’s technology tools. And everyone wants an approach that brings a holistic rather than an episodic experience.
    • It will “take a village” to achieve seamless, integrated and holistic digital health engagement. No single stakeholder in the digital health ecosystem has the solution for overcoming the frustrating fragmentation of digital health engagement solutions. There certainly is no “one-size-fits-all” approach. Health systems, payors and digital health turnkey solution providers are increasingly joining forces in this quest, with the technology provider as a “behind the scenes” extension of health systems and payors; the technology provider brings the technology infrastructure and data and work flow engineering expertise, and the health systems and payors bring the patient and plan-member relationships and care delivery and payment operations prowess. The panelists agreed unanimously that the key ingredients for successful collaborations include (a) a mutual, front-end commitment to clearly defined and articulated goals and objectives, (b) guiding principles and disciplined governance structures for managing and monitoring their relationships and performance of the endeavor, (c) an inherent ability to adapt to inevitable and sometimes unpredictable changes in the ecosystem and the industry, and (d) realistic prospects for generating a return on investment (e.g., increased revenue, reduced costs, improved patient access and outcomes, and improved provider satisfaction).
    • Digital engagement tools draw on a data ecosystem that extends well beyond the EHR, yet providers still largely look to the EHR as their primary clinical data source. All the panelists agree on three harsh realities: (a) this reliance on the EHR will likely persist for the foreseeable future, (b) clinical data from digital point solutions must find its way into the EHR so that the EHR provides a holistic view of a patient’s healthcare experience, and (c) digital engagement tools that do not provide a seamless and user-friendly way to connect with the EHR are likely to fail.
    • Transparency must not be sacrificed in the pursuit of seamlessness. Consumers, patients, regulators, pundits, the media and the class-action bar have become increasingly on the alert for digital engagement technology’s use of pixels, cookies and similar tools that track, collect and transfer personally identifiable information for secondary uses such as consumer profiling, marketing and sales. Enactment of state statutes prescribing strict transparency requirements designed to reign in such practices now seems an almost daily occurrence. Federal authorities are joining in the quest for reform by extending the reach of their existing regulatory frameworks and exploring widespread legislative initiatives. A consistent criticism and concern is the lack of full transparency with consumers and patients. All stakeholders—providers, payors and technology developers—must be ever-vigilant in monitoring these developments and remain sufficiently flexible to adapt their digital engagement transparency tools and practices in response to changing circumstances, policies and priorities.
    Authors

    Daniel F. Gottlieb

    Partner

    Chicago

    More insights

  • On the Stand with Sarah Chapin Columbia

    On the Stand with Sarah Chapin Columbia

    ARTICLE

    On the Stand with Sarah Chapin Columbia

    August 21, 2023

    Read time: 5 min

    Key takeaways
    Overview

    Sarah Chapin Columbia, a fellow in the prestigious American College of Trial Lawyers, has led 17 patent infringement, trade secrets and invalidity trials in federal courts across the country. She counsels clients on overall intellectual property (IP) strategy and positioning in several industries, including pharmaceutical and biotechnology, semiconductor, medical device and manufacturing.

    In this Q&A, Sarah shares why she became a trial lawyer, what common issue she sees her clients face in patent cases and how she uses her differentiated skill to overcome that issue and win.

    In depth

    Why did you become a trial lawyer?

    I didn’t plan to become a trial lawyer—I started out doing real estate and land use planning law. Through that, I got to operate around the edges of trial work and realized that I really liked it. I enjoyed performing in court, and it felt closer to the law than what I was doing with transactions.

    I quickly moved out of real estate to litigation and trial work. At first, I focused on general civil and criminal cases—everything from white-collar to big civil litigation to antitrust. About 10 years into that part of my career, I was asked to work with a more senior partner to build an IP practice. So, I learned patent law and started working on patent cases.

    How do you prepare for each day when you’re at trial?

    I try to get some sort of outdoor time and exercise each day. I’m an early-morning person, so I’m generally up at 4 am. I first go through what needs to happen for the day, take a walk outside, and then get with my team and go to work for our client.

    What is a common issue that you see your clients face?

    Each client needs us to take extremely complicated science, technology and business issues and present them so that the jury will understand them and reach a decision in our client’s favor.

    I primarily handle jury trials for cases that involve a very complex area of the law and a very complex area of science or technology. The trials are usually timed, so we are limited in the hours allotted to present the case to the jury.

    What is one thing about your practice that you want people to know?

    I’m trained as a lawyer, but I’m also a translator, teacher and storyteller.

    Clients come to me not because I have a deep science or technical background (I don’t), but because I will roll up my sleeves and learn the science, technology and their business and why the case or controversy matters to the company’s future. Armed with that understanding, I can translate and teach the science to convey a compelling story that will support my client’s objectives.

    Clients also know that, because I have to learn from scratch, I have a differentiated skill to teach the science, technology and business issues to the relevant audiences—judges and juries. Typically, our judges do not have science or technology backgrounds. Similarly, juries are made up of ordinary people who have been randomly selected for jury duty on any given day. These juries feature a spectrum of people, such as truck drivers, nurses, restaurant workers and everybody in between. Ultimately, they decide patent and other IP cases.

    I start with the assumption that they are all smart people but are not likely to be familiar with the subject matter. My job—and my team’s job—is to introduce the information in a way that will enable the jurors to reach a decision based on the evidence presented, even if they cannot absorb all of the complexities of the science, technology and patent law.

    What is the proudest moment of your career to date?

    You know I’ve been doing this for 36 years!

    If I had to pick one of my proudest moments, it would be when my McDermott team obtained a jury verdict for a small Japanese pharmaceutical company. Their only product had been accused of infringement and enjoined in the United States, so they couldn’t sell it.

    We won and the best part was seeing my clients’ reactions. All of them were so happy and relieved by the jury’s verdict that they started to cry.

    Even today, more than 10 years later, I receive notes of appreciation from those clients.


    Check out more trial lawyer interviews in our On the Stand series.

    Authors
    More insights

  • Chambers & Partners | Doing Business In… 2023

    Chambers & Partners | Doing Business In… 2023

    ARTICLE

    Chambers & Partners | Doing Business In… 2023

    August 2023

    Read time: 2 min

    Key takeaways
    Overview

    The fifth edition of Chambers Global Practice Guides: Doing Business In… is issued while the world’s economy is facing many uncertainties.

    This Guide serves as a reference and helpful tool for lawyers and investors alike, planning their international business and looking to understand the basic principles guiding the legal system of the contemplated jurisdictions.

    The guide, co-edited by McDermott partners Jacques Buhart and Nicolas Lafont, offers a comparison of 46 jurisdictions worldwide, with easy to digest sections, covering local legal systems, foreign investment, corporate vehicles, employment law, tax, competition law, intellectual property and data protection.

    Our lawyers provide particular insight into the laws and regulations in France.

    In depth
    Authors
    More insights

  • NLRB Undercuts Work Rules and Policies for Unionized and Nonunionized Employers

    NLRB Undercuts Work Rules and Policies for Unionized and Nonunionized Employers

    ARTICLE / CLIENT ALERT

    NLRB Undercuts Work Rules and Policies for Unionized and Nonunionized Employers

    August 17, 2023

    Read time: 8 min

    Key takeaways
    Overview

    The National Labor Relations Board (NLRB) recently issued a decision that undercuts union and nonunion employers’ ability to enforce longstanding work rules and policies. In general, this decision will lead to increased unfair labor practice charges, investigations and litigation.

    On an individual business level, there are now two options:

    1. Bet on the potential reversal of this NLRB decision in the circuit courts in the next one to two years; or
    2. Identify core policies and rules for immediate review and revision to eliminate technical ambiguity that will undermine enforceability and increase NLRB investigation and litigation costs.

    On August 2, 2023, in Stericycle, Inc., the NLRB held that work rules (for both unionized and nonunionized employers) are presumptively unlawful if an employee could interpret them to restrict rights under the National Labor Relations Act (NLRA). This presumption applies even if a rule does not actually restrict any rights, or if no other employee in the workplace would interpret the rule that way. The new standard applies to old, new and future rules—there is no safe harbor.

    In depth

    ANALYSIS AND IMPACTS

    Stericycle sweeps broadly, as a comparison of the new and old tests for evaluating policy lawfulness shows:

    Commonsense, Former Standard: Workplace rules are lawful unless reasonable employees would interpret those rules to restrict rights protected by the NLRA.

    Stericycle addresses “facially neutral” rules that do not expressly restrict employee rights under the NLRA. Rules prohibiting the unauthorized disclosure of confidential business information to outside entities or promoting a respectful work environment are classic examples.

    These rules serve important company interests, such as fostering compliance and providing a safe and supportive working environment. And, until now, the NLRB placed traditional work rules like these into one of three categories:

    1. Rules that are presumptively lawful (e.g., rules prohibiting disclosure of a company’s confidential, proprietary or trade secret information);
    2. Rules that require a case-by-case review (e.g., social media policies); and
    3. Rules that are unlawful (e.g., rules prohibiting employees from discussing wages).

    The NLRB assigned rules to their appropriate category by applying a clear and straightforward test: Would a reasonable employee (i.e., one who understands why work rules exist and what they hope to achieve) believe the rule in question restricts his or her rights under the NLRA? For example, would an employee interpret a rule prohibiting disclosure of the company’s confidential and trade secret information to also prohibit discussions of working conditions with their coworkers? The answer was presumptively “no,” and the rule was presumptively lawful.

    The New Standard: Workplace rules are presumptively unlawful where employees could interpret those rules to restrict rights protected by the NLRA.

    Now, a facially neutral work rule or policy is presumptively unlawful if any employee could interpret the rule/policy to restrict rights under the NLRA. It does not matter if the rule does so, or if the same (or every other) employee could just as reasonably interpret the same rule or policy to have no bearing on their rights.

    Stericycle redefines the “reasonable employee.” This hypothetical employee no longer understands the rationale for workplace rules and is incapable of viewing a particular rule within the larger context of his or her employment. Instead, the NLRB’s new paradigm is “readily inclined to interpret [the rule] more broadly to restrict or prohibit” employee rights under the NLRA.

    This new outlook predetermines the outcome of the NLRB’s new analysis: An employee predisposed to believe that every work rule restricts his or her rights under the NLRA could believe a rule prohibiting disclosure of a company’s confidential and trade secret information also prohibits discussions of working conditions with their coworkers. After all, working conditions are not public information and could be confidential, even if the rule at issue clearly focuses on the disclosure of sales information.

    Employers may be asking themselves: What if no employee so testifies? Or what if employees testify en masse under oath that this wasn’t their reading or the reading of their coworkers? The answer to these questions is that it doesn’t matter. Stericycle is not evidence-dependent; in each case, its standard merely tests the imagination of the NLRB and its counsel to think of any reason to strike down a rule.

    The Stericycle standard is designed to invalidate most work rules as presumptively unlawful. While the NLRB provides employers an “affirmative defense” to rebut the presumption, that will require proving the challenged rule (1) advances legitimate business interests and (2) cannot be achieved by a more narrowly tailored rule. This will prove a tall, if not impossible, task.

    WHAT’S NEXT?

    Employers must still regulate employee conduct in the workplace but now will need to be selective in announcing rules and more narrowly focused when drafting them. Some rules (e.g., attendance or safety) will be easier. Others will require Herculean efforts and will likely regulate less tomorrow than yesterday.

    As a starting point, consider the handbook rules in the crosshairs in Stericycle:

    • Retaliation: “All parties involved in the investigation [of a harassment complaint] will keep complaints and the terms of their resolution confidential to the fullest extent practicable.”
    • Electronic Communication Policy: “A substantial portion of our business is transacted by telephone and over the wide area network. Therefore, in order to maintain the efficiency of these systems non-business usage must be restricted. Phone and data lines must be kept open for business purposes. Accordingly, personal telephone calls and e-mails should be infrequent and brief, and limited to urgent family matters.”
    • Use of Personal Electronics: “The use of personal cell phones or other personal electronic devices such as MP3 players is prohibited in waste processing, warehouse, loading and unloading areas during operating hours and any areas subject to vehicle movement at any time…Personal mobile phones and all other personal mobile electronic devices are to be kept in team members’ lockers. Personal phone calls and use of personal electronic devices shall be restricted to meal and break periods. Violation of this policy may result in disciplinary action up to and including termination.”
    • Personal Conduct: “In order to protect everyone’s rights and safety, it is the Company’s policy to implement certain rules and regulations regarding your behavior as a team member. Conduct that maliciously harms or intends to harm the business reputation of Stericycle will not be tolerated. You are expected to conduct yourself and behave in a manner conducive to efficient operations. Failure to conduct yourself in an appropriate manner can lead to corrective action up to and including termination. The following are some examples of infractions which could be grounds for corrective action up to and including termination, however[,] this list is not all-inclusive…Engaging in behavior that is damaging to Stericycle’s reputation.”
    • Conflict of Interest: “Stericycle will not retain a team member who directly or indirectly engages in the following: An activity that…adversely reflects upon the integrity of the Company or its management.”

    Each rule is at risk under Stericycle and will remain so until the new standard is challenged on appeal (which seems probable). Circuit courts previously voiced concerns over similar standards, and it is possible the new test will not withstand scrutiny.

    In the interim, Stericycle will open the floodgates to legal challenges to employee handbooks and other employee rules and policies in both union and nonunion settings, leaving employers to decide on policy revisions, settlement strategy or litigation. For example, routine and commonsense work rules prohibiting “loud, abusive or foul language” or “false, vicious, profane or malicious statements about an employer or its employees” will be challenged as unlawful by one-off employees or unions seeking to inspire organizing campaigns. These challenges will often be successful. But giving up or turning a blind eye to abusive conduct can create a hostile work environment that negatively impacts employee morale and retention. Employers facing this dilemma now possess two unpalatable options: regulate employee misconduct at the risk of litigation or permit a toxic work environment.

    Still, employers can and should take steps to mitigate these risks and fend off years of uncertainty by identifying and modifying core work rules and policies. Potential action items include:

    • Limiting work rules to only regulate truly important issues.
    • Narrowing the scope of work rules and, if practicable, providing examples of the specific conduct prohibited versus what is permitted (e.g., clarifying that a company’s policy prohibiting “loud, abusive or foul language” in the workplace does not prohibit any employee from raising concerns about work conditions to their supervisor or designated HR representative).
      • This modification should mitigate (if not eliminate) the risk that employees will misinterpret neutral rules to restrict their rights under the NLRA.
    • Explaining the scope and intent of work rules to employees, whether in the text of the rule, via employee training or both.
      • This is particularly important for rules prohibiting the unauthorized disclosure of confidential business information to outside entities. Identifying the types of confidential, proprietary and trade secret information at issue, and why they must be safeguarded, will go a long way towards insulating these rules from challenge.
    • Consider adding disclaimers to certain rules (e.g., “This rule neither prohibits nor limits discussion of working conditions with coworkers or any other right protected by the NLRA.”).
    Authors
    More insights

  • Noncompulsory Counterclaims Don’t Confer Appellate Jurisdiction

    Noncompulsory Counterclaims Don’t Confer Appellate Jurisdiction

    ARTICLE

    Noncompulsory Counterclaims Don’t Confer Appellate Jurisdiction

    Aug 17, 2023

    Read time: 5 min

    Key takeaways
    Overview

    The US Court of Appeals for the Federal Circuit determined that it does not have appellate jurisdiction to review noncompulsory patent counterclaims in a case otherwise unrelated to the originally asserted patents. Teradata Corp. v. SAP SE, Case No. 22-1286 (Fed. Cir. Aug. 1, 2023) (nonprecedential) (Lourie, Taranto, Hughes, JJ.)

    Teradata makes and sells data warehouse systems and services. SAP develops and sells software. The two companies began collaborating while SAP was simultaneously developing its own database (HANA) and component software. SAP eventually informed Teradata that it would stop selling certain Teradata products. Teradata sued SAP, alleging misappropriation of trade secrets on the theory that SAP used Teradata’s proprietary information to create HANA. Teradata also alleged various antitrust violations, arguing that SAP “illegally tied” HANA and HANA’s supporting software. In response, SAP filed counterclaims against Teradata for allegedly infringing SAP patents related to database organization and optimization. On Teradata’s motion, the district court agreed to sever one of the four patent infringement claims but allowed the others to proceed. The district court reasoned that Teradata’s claims and SAP’s counterclaims all arose from “the same transaction or occurrence,” namely SAP’s development of HANA.

    The district court granted summary judgment to SAP on Teradata’s antitrust and technical trade secret claims and stayed proceedings on Teradata’s business trade secret claim and to Teradata on SAP’s patent counterclaims. Teradata appealed to the Federal Circuit.

    SAP moved to transfer the appeal to the Ninth Circuit. The Federal Circuit denied the motion but instructed the parties to address the jurisdictional issue in the merits brief. 28 U.S.C. § 1295(a)(1) grants the Federal Circuit exclusive appellate jurisdiction over final decisions in which a party claims or asserts a compulsory counterclaim related to patents. As it relates to this case, the issue was whether SAP’s patent infringement counterclaims were “compulsory,” meaning SAP would be unable to later sue on these patent infringement allegations “if it did not press them in this action.”

    The Federal Circuit began by looking at Federal Rules of Civil Procedure 13(a), which states that a counterclaim is “compulsory” if it arises from the same transaction or occurrence as a plaintiff’s claim. The Court explained that it uses three tests to determine whether the transaction or occurrence is sufficiently related between the claim and counterclaim:

    1. Whether the legal and factual issues are substantially the same
    2. Whether the evidence will be substantially the same
    3. Whether there is “a logical relationship between the claim and the counterclaim.”

    Taken together, these tests essentially ask if there is substantial overlap between what the plaintiff and the defendant must establish to succeed on the claim and counterclaim, respectively.

    The Federal Circuit found that the first two tests clearly weighed against SAP’s counterclaim being compulsory. While an understanding of the accused products and alleged trade secrets would be necessary for both the claim and the counterclaim, “same-field overlap” is not enough to make the issues or necessary evidence “substantially the same.”

    As to the third test, the Federal Circuit found an insufficient “logical relationship” between Teradata’s trade secret and antitrust claims and SAP’s patent infringement counterclaims. The Court noted that one key consideration was that SAP’s products were the subject of the trade secret misappropriation and antitrust claims, but Teradata’s products were the subject of the patent infringement counterclaims, mitigating against any showing of a strong logical relationship. The Court also noted that SAP’s counterclaims did not relate to the validity of Teradata’s trade secrets or SAP’s monopoly but to the separate issue of Teradata’s alleged patent infringement. Thus, the Court concluded that the two sides’ claims did not “arise out of the same transaction or occurrence” and therefore SAP’s counterclaims were not compulsory.

    The Federal Circuit concluded that since SAP’s counterclaims were noncompulsory, they did not confer appellate jurisdiction. However, the Federal Circuit noted that if the Ninth Circuit were to sever SAP’s patent counterclaims under Fed. R. Civ. P. 21, a judgment on SAP’s independent patent claims would be appealable to the Federal Circuit. However, as the case was presented, the Federal Circuit determined that it did not have jurisdiction over the noncompulsory counterclaims or the non-patent claims, and therefore transferred the appeal to the Ninth Circuit.

    Practical Note: For defendants deciding whether to assert noncompulsory patent counterclaims or institute a separate action for infringement, the path to appeal should be a necessary consideration.

    Authors
    More insights
    Endnotes

  • Effective January 2024: Illinois Joins Growing List of States that Require Attorney General Notice of Healthcare Transactions

    Effective January 2024: Illinois Joins Growing List of States that Require Attorney General Notice of Healthcare Transactions

    ARTICLE / CLIENT ALERT

    Effective January 2024: Illinois Joins Growing List of States that Require Attorney General Notice of Healthcare Transactions

    August 16, 2023

    Read time: 4 min

    Key takeaways
    Overview

    On August 11, 2023, Governor J. B. Pritzker signed Illinois House Bill 2222 into law (Public Act 103-0526). Public Act 103-0526 amends certain provisions of the Illinois Antitrust Act, the State Finance Act and the Illinois Health Facilities Planning Act to grant the Illinois attorney general (IL AG) oversight over a broad array of transactions that involve healthcare facilities. The law will become effective January 1, 2024.

    In depth

    Public Act 103-0526 amends certain provisions of the Illinois Antitrust Act, the State Finance Act and the Illinois Health Facilities Planning Act to grant the IL AG oversight over a broad array of transactions that involve healthcare facilities. The legislation that would become Public Act 103-0526 passed the Illinois House of Representatives on March 24, 2023, arrived in the Illinois Senate on March 27, 2023, and passed both chambers of the General Assembly on May 18, 2023. The General Assembly then sent the legislation to Governor Pritzker for his approval on June 16, 2023, which he provided on August 11, 2023.

    As we reported in a previous On the Subject regarding House Bill 2222, Public Act 103-0526 requires 30 days’ prior notice to the IL AG of any merger, acquisition or contracting affiliation between two or more healthcare facilities or provider organizations not previously under common ownership or contracting affiliation (covered transactions). Transactions that are submitted to the Illinois Health Facilities and Services Review Board in compliance with the Illinois Health Facilities Planning Act get automatically submitted to the IL AG. Any healthcare facility or provider organization that is a party to a covered transaction and files a premerger notification to the federal antitrust enforcement agencies in compliance with the Hart-Scott-Rodino Act must simultaneously provide a copy of such filing to the IL AG.

    Any healthcare facility or provider organization that is party to a covered transaction not described above (i.e., a transaction that does not require a filing under the Hart-Scott-Rodino Act or a change of ownership filing with the Illinois Health Facilities and Services Review Board) would be required to provide written notice to the IL AG.

    The IL AG can request additional information, as it deems necessary, within 30 days of receiving notice of the covered transaction. If the IL AG requests additional information, the covered transaction may not proceed until 30 days after the parties have substantially complied with the request. Failure to comply with the IL AG notice requirements and responses to IL AG requests for additional information would expose the healthcare facility or provider organization to a penalty of $500 for each day in violation, after a 10-day cure period, which when collected is then deposited into a new antitrust enforcement fund.

    While the scope of Public Act 103-0526 is quite broad, its full impact remains to be seen. Much depends upon how active the IL AG is in requesting additional information from applicants. Healthcare facilities and provider organizations that are concerned about potential delays or onerous requests for information as a result of Public Act 103-0526 should consult with their legal counsel to determine the appropriate time to file the required notice to the IL AG.

    For more information or for assistance with Public Act 103-0526, please contact one of the authors.

    Authors

    Sandra M. DiVarco

    Partner

    Chicago

    Sumaya Noush

    Partner

    Chicago

    More insights

  • New MHPAEA Guidance Regarding NQTLs: Network Access and Composition

    New MHPAEA Guidance Regarding NQTLs: Network Access and Composition

    ARTICLE / CLIENT ALERT

    New MHPAEA Guidance Regarding NQTLs: Network Access and Composition

    August 16, 2023

    Read time: 5 min

    Key takeaways
    Overview

    Recently proposed regulations attempt to ensure that health plans allow access to mental health or substance use disorder (MH/SUD) benefits as easily as medical or surgical (M/S) benefits. The proposed regulations, issued by the US Departments of Health & Human Services, Labor and Treasury (the Departments) on July 25, 2023, implement changes to the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) and were accompanied by a Technical Release (the Technical Release). The Technical Release invites comment on certain provisions of the proposed regulations relating to data requirements for Non-Quantitative Treatment Limitations (NQTLs) governing network composition. In a recent On the Subject, we summarized the proposed regulations, and this On the Subject examines the Technical Release.

    In depth

    BACKGROUND

    The MHPAEA prevents group health plans and health insurance issuers that provide MH/SUD benefits from imposing more favorable limitations on medical/surgical M/S benefits, including with respect to annual and lifetime dollar limits, financial requirements and treatment limitations (both quantitative and non-quantitative treatment limitations, i.e., NQTLs)

    Quantitative treatment limitations include deductibles, copayments and coinsurance, as well as quantitative treatment limitations that are expressed numerically, such as day or visit limits. In contrast, NQTLs are generally non-numerical requirements that limit the scope or duration of benefits; these include prior authorization requirements, step therapy and standards for provider admission to participate in a network, including reimbursement rates.

    The Consolidated Appropriations Act, 2021 amended the MHPAEA to require plans to perform and document NQTL comparative analyses and provide them to the Departments or an applicable state authority upon request. The proposed regulations detail the comparative analysis documentation requirement. They would, among other things, require plans to demonstrate that their NQTLs comply with MHPAEA in both form and operation. The proposed regulations reflect the Departments’ concerns about how NQTLs related to network composition affect access to MH/SUD benefits, which impact access to MH/SUD providers.

    THE TECHNICAL RELEASE

    The Technical Release offers a data-driven approach to network composition and network access requirements. The Departments invite comment on the type, form and manner of data that plans should be required to collect and evaluate along with other relevant data as part of their comparative analyses. The Departments also invite comments on a potential enforcement safe harbor under which plans would be permitted to demonstrate compliance.

    Data Collection

    The Departments outline four specific types of data that they are considering requiring plans to collect and evaluate as part of their comparative analyses for NQTLs related to network composition. These include:

    • Out-of-network utilization
    • Percentage of in-network providers actively submitting claims
    • Time and distance standards
    • Reimbursement rates

    The Departments propose using the four types of data listed above to assist with their respective reviews and evaluations of whether a plan’s NQTLs related to network composition comply with MHPAEA.

    Enforcement Safe Harbor

    The Departments propose creating an enforcement safe harbor with respect to NQTLs related to network composition for plans that meet or exceed specific data-based standards identified in future guidance. According to the Technical Release, the safe harbor could include data such as in-network and out-of-network utilization rates (including data related to provider claim submissions), network adequacy metrics (including time and distance data, and data on providers accepting new patients) and reimbursement rates (including as compared to billed charges).

    The Departments caution that they expect that the NQTL network composition enforcement safe harbor standards “would set a high bar” to meet for enforcement relief.

    NEXT STEPS

    The proposed regulations and Technical Release governing network composition would, if adopted in final form, add significant new compliance burdens to an already burdensome rule. The Technical Release provides helpful information regarding the type of data that the Departments expect for network composition NQTL determinations. In addition, the Technical Release clarifies that the Departments propose an enforcement safe harbor for only network composition NQTLs, not all NQTLs.

    Practically, the proposed regulations and Technical Release will probably require health plans to eliminate certain NQTLs on MH/SUD benefits and expend greater resources to comply with the MHPAEA, while likely driving up the cost of providing health benefits. As a result, health plan sponsors and service providers should stay updated on the proposed regulations, any potential revisions prior to their finalization and their outsized impact on the operation of health plans.

    For any questions regarding mental health parity or for assistance submitting comments concerning the proposed regulations, please contact your regular McDermott lawyer or one of the authors.

    Authors

    Sarah G. Raaii

    Partner

    Chicago

    More insights

  • Decoding Genomic Data Security: Lessons from FTC’s Vitagene Enforcement and the NIST CSF Profile for Genomic Data

    Decoding Genomic Data Security: Lessons from FTC’s Vitagene Enforcement and the NIST CSF Profile for Genomic Data

    ARTICLE / REPORT

    Decoding Genomic Data Security: Lessons from FTC’s Vitagene Enforcement and the NIST CSF Profile for Genomic Data

    August 15, 2023

    Read time: 2 min

    Overview

    Remarkable progress in DNA and RNA sequencing have democratized the generation and analysis of genomic data across diverse industry sectors, including biopharmaceutical research, healthcare, consumer ancestry, law enforcement, agriculture and wellness testing. However, these advances have simultaneously escalated cybersecurity risks associated with the collection, processing, and maintenance of genomic data. This burgeoning challenge has prompted state attorneys general and federal agencies to take action to safeguard consumers and ensure responsible genomic data management. Here we examine recent state and federal enforcement actions and guidance from the National Institute of Standards and Technology (NIST) that address the responsible collection, storage and use of genomic data. We summarize key issues and recommendations to help genomic community stakeholders manage and reduce cybersecurity risks.

    In depth
    Tabs

    Jennifer S. Geetter

    Partner

    Washington, DC

    Sam Siegfried

    Partner

    Chicago

    More insights
    Endnotes

  • Better Than a Snow Day: The PBGC Provides One-Time Section 4010 Reporting Waiver

    Better Than a Snow Day: The PBGC Provides One-Time Section 4010 Reporting Waiver

    ARTICLE / CLIENT ALERT

    Better Than a Snow Day: The PBGC Provides One-Time Section 4010 Reporting Waiver

    August 15, 2023

    Read time: 4 min

    Key takeaways
    Overview

    Acknowledging uncommon market conditions, the Pension Benefit Guaranty Corporation (PBGC) announced Technical Update Number 23-1 (the Update), which provides a one-time waiver of certain reporting requirements for some underfunded defined benefit pension plans under the Employee Retirement Income Security Act of 1974 (ERISA). However, to qualify for the waiver, pension plan sponsors still need to timely notify the PBGC.

    In depth

    BACKGROUND

    Generally, ERISA Section 4010 requires plan sponsors (and controlled group members) of certain underfunded single-employer defined benefit plans to provide financial and actuarial financial information to the PBGC each year. Pension plans falling below the 80% “at-risk” funding target attainment percentage (4010 FTAP) must provide specified information via an electronic ERISA Section 4010 filing.

    The PBGC is authorized to assess a penalty for failing to make this filing. In January 2023, this penalty was increased to a maximum of $2,586 for each day a filing is overdue. In addition to filing penalties, ERISA Section 4010 filings generally are unpopular with plan sponsors for several reasons:

    • Extensive financial data must be reported to the PBGC for all US-controlled group members;
    • Pension plan participants receive information on the ERISA Section 4010 filing in the annual funding notice for the pension plan; and
    • The PBGC places the plan sponsor on a watch list for future acquisitions and divestitures and can require additional pension funding or transaction financing to protect pension plan assets and funding.

    TECHNICAL UPDATE NUMBER 23-1

    In the Update, the PBGC notes that it expects recent “atypical and almost unprecedented” market conditions to affect the liability and asset measures that determine whether a 4010 filing is required. These conditions may cause many defined benefit plans to have a 4010 FTAP below 80%, triggering an ERISA Section 4010 reporting requirement. To provide relief, the PBGC will provide a one-time waiver of the ERISA Section 4010 filing requirements if all of the following conditions are met:

    • An ERISA Section 4010 reporting requirement did not apply for the last five years.
    • Either:
      • None of the defined benefit plans in the controlled group has a market-based 4010 FTAP (as defined in the guidance) that falls below 85% or
      • The market-based aggregate funding shortfall (as defined in the guidance) does not exceed $15 million.
    • If a defined benefit plan maintained by a controlled group member has a 4010 FTAP below 80%, then the plan’s valuation date must fall on or after October 1, 2022, and before March 1, 2023.

    To utilize this relief, a plan sponsor must notify the PBGC no later than 15 days before the date the ERISA Section 4010 filing would have been due if not for the waiver. Entities using the waiver must send an email to ERISA.4010@pbgc.gov with the subject line “Technical Update 23-1 Waiver.” Additional information about filing can be found on PBGC’s 4010 reporting webpage.

    WHAT’S NEXT?

    Defined benefit plan sponsors should closely review this new relief with their lawyers and actuaries to determine whether the reporting waiver applies. For more information about the waiver or the reporting requirements, please contact one of the authors or your regular McDermott lawyer.

    Authors

    Todd A. Solomon

    Partner

    Chicago

    More insights

  • California Publishes Draft Regulations on Filing Requirement for Healthcare Entity Transactions

    California Publishes Draft Regulations on Filing Requirement for Healthcare Entity Transactions

    ARTICLE / CLIENT ALERT

    California Publishes Draft Regulations on Filing Requirement for Healthcare Entity Transactions

    August 14, 2023

    Read time: 10 min

    Key takeaways
    Overview

    California’s Office of Health Care Affordability (OHCA) has published draft regulations on the healthcare transaction notice requirement that will become effective on April 1, 2024. Entities entering into healthcare transactions in California that will close on or after April 1, 2024, should be aware of the requirement to provide 90 days’ prior notice of certain material changes and the potential burdensome review process that could delay the closing of such transactions by several months. The OHCA is planning to hold a public workshop for the draft regulations on August 15, 2023, both in person and virtually, and will accept public comments on the draft regulations through August 31, 2023. OHCA plans to submit the final regulations as an emergency rulemaking package in October 2023, so interested stakeholders should consider submitting comments, closely monitoring these developments and taking proactive steps to prepare any transactions currently underway to comply with these new requirements.

    In depth

    Overview of the Transaction Notice Requirement

    California Senate Bill 184 (SB 184) passed on June 30, 2022, establishing the OHCA to contain healthcare spending in the state. Among the agency’s regulatory powers is the ability to review certain proposed healthcare transactions closing on or after April 1, 2024. Unlike the California Office of the Attorney General (AG), in its review of nonprofit health facility transactions in California, the OHCA does not have the ability to stop the transaction or impose conditions on the transaction. However, the OHCA can require the production of a market impact report that could significantly delay the transaction.

    At a high level, SB 184 requires a “health care entity” (defined as a provider, payor or fully integrated delivery system) entering into a transaction involving the sale or transfer of control of a material amount of its assets or operations to provide at least 90 days’ prior written notice of the transaction to the OHCA. After the health care entity provides notice, the agency then has 60 days to either advise the health care entity of its determination to conduct a cost and market impact review (CMIR) or provide a written waiver from such review. OHCA will issue a preliminary report upon completion of the CMIR. Then, after allowing the parties and the public to provide input, the OHCA will issue its final report. No transaction going through the CMIR process may close until 60 days following the OHCA’s issuance of the final report.

    The OHCA is required to conduct a CMIR if the transaction is “likely to have a risk of a significant impact on market competition, the state’s ability to meet cost targets, or costs for purchasers and consumers.” The report would look at factors such as changes in size of and market share in a particular service or geographic region, prices for services compared to other providers, and quality, equity, costs and access.

    The CMIR process is intended to apply additional regulatory scrutiny to transactions that may have previously slipped under the government’s radar. As such, SB 184 explicitly exempts certain transactions from the material change transaction notice process because they are already subject to review by a California agency; such transactions include the following:

    • Transactions involving “health care service plans” that are subject to review by the director of the Department of Managed Health Care for cost impact or market consolidation under the Knox-Keene Health Care Service Plan Act of 1975
    • Transactions involving health insurers that are subject to review by the state insurance commissioner
    • Agreements or transactions in which a county is purchasing, acquiring, or taking control, responsibility or governance of an entity to ensure continued access in that county
    • Transactions involving nonprofit health facilities that are already subject to AG review.

    Draft Regulations

    The draft regulations clarify a number of issues that were not addressed in the original statute. The draft regulations expand the definition of a “health care entity,” establish materiality thresholds, describe the information that must be submitted in the transaction notice, provide additional details on the timeline of the CMIR process and describe the factors that the OHCA will consider in determining whether to conduct a CMIR. However, the following draft regulations are subject to change before the OHCA promulgates final regulations in October:

    • Health care entity definition: The regulations state that the follow entities are also considered a health care entity that must provide notice of a material change:
      • Pharmacy benefit managers
      • Management services organizations that provide management services for a health care entity
      • Any affiliates, subsidiaries or other entities that control, govern or are financially responsible for the health care entity or that are subject to the control, governance or financial control of the health care entity.
    • Health care entity materiality: A health care entity must submit notice of a material change if “the transaction involves” any of the following parties (but note that this part of the regulations may make more sense if it required a health care entity to provide notice if it is one of the following parties):
      • A health care entity with annual revenue of at least $25 million or that owns or controls at least $25 million of California assets
      • A health care entity with annual revenue of at least $10 million or that owns or controls at least $10 million of California assets and is involved in a transaction with a health care entity with annual revenue of at least $25 million or that owns or controls at least $25 million of California assets
      • A health care entity located in or serving at least 50% of patients who reside in a health professional shortage area.
    • Material change: Each of the following types of changes constitute a “material change” for which a health care entity must provide notice if all other requirements are met:
      • The transaction has a proposed fair market value of at least $25 million
      • The transaction is likely to increase annual revenue of a health care entity by at least $10 million or 20%
      • The transaction involves the sale, transfer or disposition of 20% or more of the assets of any health care entity
      • The transaction involves a change of control of 10% or more of a health care entity, or a transfer of full or partial voting control
      • The transaction contemplates an entity negotiating or administering contracts with payors on behalf of one or more providers and involves an affiliation, partnership, joint venture, accountable care organization, parent corporation, management services organization or other organization
      • The transaction would form a new entity for provision of healthcare services in California that is projected to have at least $25 million in annual revenue or assets
      • The transaction involves a health care entity joining, merging or affiliating with another health care entity, affiliation, partnership, joint venture or parent corporation where the health care entity has at least $10 million in annual revenue
      • The transaction involves changing the form of ownership of a health care entity, including changes from a physician-owned to a private equity-owned entity or from a publicly held to a privately held entity
      • The transaction involves a health care entity that has consummated any transaction regarding provision of healthcare services in California with another party to the transaction in the 10 years prior to the transaction subject to the notice.
    • Required submissions: A substantial amount of information must be submitted in narrative form, with supporting documentation, and all information submitted will be publicly available unless the parties request to keep certain documents confidential. This includes, among other requirements:
      • Descriptions of the entities party to the transaction, including name, address, geography served, entity type, corporate structure, applicable California licenses and annual revenue
      • Details about the transaction, including the goals of the transaction, a summary of the terms of the transaction, a statement of why the transaction is necessary or desirable, a description of the general public impact or benefits of the transaction, a description of the expected competitive impacts of the transaction, and a description of any actions or activities to mitigate any potential adverse impacts of the transaction on the public
      • A description of any transaction in the prior 10 years involving the health care entities in the proposed transaction that affected or involved the provision of health services
      • A description of any pending or planned material changes occurring between the submitting entity and any other entity in the 12 months following the date of the notice
      • Copies of the current agreement(s) and term sheet(s) governing the transaction
      • If applicable, pro forma post-transaction balance sheet(s) for any surviving or successor entity
      • Organization charts for all entities to the transaction, pre- and post-transaction
      • Certified financial statements for the prior three (3) years for all entities party to the transaction
      • If applicable, a copy of the Premerger Notification and Report Form, with attachments, submitted to the Federal Trade Commission (FTC) pursuant to the Hart-Scott-Rodino (HSR) Act.
    • Timing: If the OHCA decides to conduct a CMIR, the OHCA will have 90 days to complete the preliminary report, but may extend this by an additional 45 days, or toll either of these time periods if it is waiting for additional information from the parties to the transaction. Within 10 business days of the issuance of the preliminary report, the parties and the public may submit written comments. The OHCA shall issue a final report within 30 days of the close of the comment period, unless the OHCA chooses to extend this time for good cause (e.g., if the OHCA requires additional time to review and evaluate the written comments).
    • Determination of whether to conduct a CMIR: In determining whether to conduct a CMIR, the OHCA may base its decision on any one or more of the following factors:
      • If the transaction may result in a negative impact on the availability or accessibility of healthcare services, including the health care entity’s ability to offer culturally competent care
      • If the transaction may result in a negative impact on costs for payers, purchasers or consumers, including the ability to meet any healthcare cost targets established by the OHCA
      • If the transaction may lessen competition or tend to create a monopoly in any geographic service areas impacted by the transaction
      • If the transaction directly affects a general acute care or specialty hospital
      • If the transaction may negatively impact the quality of care
      • If the transaction between a health care entity located in California and an out-of-state entity may increase the price of healthcare services or limit access to healthcare services in California.

    Takeaways

    • Under the draft regulations, a management services organization will be considered a health care entity for purposes of the transaction notice requirement. The draft regulations reflect the OHCA’s understanding of and focus on private equity transactions and “friendly physician” arrangements in California.
    • The notice requirement and CMIR process, as currently drafted, has the potential to delay the closing of transactions by several months. Health care entities entering into material transactions in California should factor this into their overall transaction timeline. Stakeholders should also consider the costs of preparing the notice to the OHCA and the additional costs if the OHCA decides to conduct a CMIR (for which the costs are reimbursable from the parties to the transaction).
    • The notice requirement does not appear to have any exemptions for health care entities under severe financial distress or that are undergoing bankruptcies, and there does not appear to be an option for expedited review.
    • The draft regulations are subject to change, and stakeholders will have opportunities in the month of August to influence the development of the final regulations. The OHCA is planning to host a public workshop for the draft regulations on August 15, 2023. Members of the public may attend in person or online. The OHCA is also accepting written comments on the draft regulations through August 31, 2023. For more information, please see the notice linked here.
    • After the public workshop and receipt of public comments in August, the OHCA plans to submit the final regulations as an emergency rulemaking package in October 2023.
    Authors

    Cathy Ren

    Partner

    Los Angeles

    More insights